Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenytoin hypersensitivity.

E Finan1, A Trofa, K Williams

  • 1Department of Internal Medicine, St. Agnes Hospital, Baltimore.

Maryland Medical Journal (Baltimore, Md. : 1985)
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of progressive myopia with 0.01% Atropine in children and adolescents: an Italian 4-year follow-up study.

La Clinica terapeutica·2024
Same author

Neonatal resuscitation guidelines update: A case-based review.

Paediatrics & child health·2012
Same author

High-fidelity simulator technology may not be superior to traditional low-fidelity equipment for neonatal resuscitation training.

Journal of perinatology : official journal of the California Perinatal Association·2011
Same author

Improved procedural performance following a simulation training session may not be transferable to the clinical environment.

Journal of perinatology : official journal of the California Perinatal Association·2011
Same author

Failure of pediatric and neonatal trainees to meet Canadian Neonatal Resuscitation Program standards for neonatal intubation.

Journal of perinatology : official journal of the California Perinatal Association·2009
Same author

Early discontinuation of intravenous prostaglandin E1 after balloon atrial septostomy is associated with an increased risk of rebound hypoxemia.

Journal of perinatology : official journal of the California Perinatal Association·2008
Same journal

Adherence to the JNC VI guidelines for the treatment of hypertension in the resident clinic.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Seroprevalence study of Hantavirus infection in the community based population.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Pneumomediastinum: the Valsalva crunch.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Hepatic hydrothorax: diagnosis and management. Case report and review of the literature.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

A case of post-streptococcal reactive arthritis.

Maryland medical journal (Baltimore, Md. : 1985)·2000
Same journal

Sexual practices of older adults in a high HIV prevalence environment.

Maryland medical journal (Baltimore, Md. : 1985)·2000
See all related articles

Phenytoin hypersensitivity, a severe reaction to diphenylhydantoin, can be fatal. Patients must be informed about potential complications and early warning signs of adverse drug reactions.

Area of Science:

  • Pharmacology
  • Clinical Toxicology

Background:

  • Phenytoin (diphenylhydantoin) is an anticonvulsant medication.
  • Hypersensitivity reactions to phenytoin can occur.
  • These reactions pose a significant risk to patient safety.

Observation:

  • Phenytoin hypersensitivity is a serious adverse drug reaction.
  • The reaction is linked to the chemical diphenylhydantoin.
  • Early recognition of symptoms is crucial.

Findings:

  • Phenytoin hypersensitivity is a potentially fatal condition.
  • Understanding the signs of this adverse drug reaction is vital for management.
  • Patient education on potential complications is necessary.

Implications:

Related Experiment Videos

  • Informing patients about phenytoin hypersensitivity can improve early detection.
  • Prompt recognition of sentinel signs may prevent severe outcomes.
  • This highlights the importance of pharmacovigilance for diphenylhydantoin.